Розробка дитячої лікарської форми з L-карнітином by Bezchasnyuk, O. M. et al.
ВІСНИК ФАРМАЦІЇ 1(77)201426 ISSN 1562-7241
Recommended by Doctor of Pharmacy, professor O.I.Tikhonov 
UDC 615.014.24:615.456.1:615.27:612.394.2
THE DEVELOPMENT OF THE DOSAGE FORM WITH 
L-CARNITINE FOR CHILDREN
O.M.Bezchasnyuk, T.V.Zborovska, S.M.Kovalenko
National University of Pharmacy
Key words: manufacture of dosage forms for children; L-carnitine; syrup
Treatment of metabolic disorders in children and adults of all ages is the current serious problem. 
Nowadays much attention is paid to the treatment with drugs based on L-carnitine. The drug for 
children in the form of a syrup containing L-carnitine has been researched and developed. Drugs 
with the dosed L-carnitine for children are absent at the modern pharmaceutical market of Ukraine. 
Suitable dosage forms for children of all ages are liquid forms, including syrups. The drug technology 
has been developed and tested in the academic research technological laboratory of the National 
University of Pharmacy for introduction into the pharmaceutical industry of the country. To develop 
this technology the literature has been analyzed; a number of similar drugs has been identified and 
their qualitative composition has been studied. The quantitative composition of the drug developed 
has been determined experimentally. Based on the data of the pharmacological activity of L-carnitine 
the concentration of the active substance has been selected. The preservatives, modifiers of acid-
base properties and flavours have been selected. The sequence of manufacturing operations, which 
allows creating a quality product, has been determined. A stepwise manufacture of the drug in the 
flowchart of the technological process has been described. The pharmacotechnological quality 
characteristics of the medicinal dosage form proposed, namely the drug appearance, pH, relative 
density and transparency of the resulting solution, have been studied. The results of this work have 
been included in the pharmaceutical development of the drug.
The treatment of metabolic disorders is one of the 
serious problems in modern medicine. Hundred years 
of active research of the metabolic role of L-carnitine 
pathogenetically justifies its use in various pathological 
conditions both in adults and children, including new-
borns [7, 8, 9].
In recent years much attention is paid to the use of 
L-carnitine in pediatrics. L-carnitine is necessary from 
the beginning of the child’s life. Taking L-carnitine during 
pregnancy has a positive impact not only on the mother’s 
state, but also on development and the vital activity of 
the fetus, improving the work of the lungs and the car-
diovascular system, as a result, the risk of the sudden 
infant death syndrome reduces. Newborns differ by defi-
ciency of the energy metabolism. Disorders of the ener-
gy metabolism and deficiency of carnitine significantly 
exacerbate in the case of prematurity, damage of the ner- 
vous system, respiratory disorders, cardiovascular disease, 
anemia and hyperbilirubinemia. L-carnitine penetrates 
into the organism of an infant with the breast milk or 
artificial feeding. 
The positive action of L-carnitine has been revealed 
in different spheres of the neuropsychic response due to 
neurodynamic processes improvement, their activation, 
switching and regulation; it provides increase of the re-
sistance to physical, intellectual and emotional loads. 
The most expressed positive effect of the drug is ob-
served with the prolonged use (several months without 
a break), especially in cases of high exhaustion, psy-
chophysical overload and in gross organic lesions of the 
nervous system [1, 9-14].
L-carnitine is used in pediatrics in the composition 
of drugs for adults “Cardonat” and “Trimetabol”, in pa-
tient information leaflets dosages for children are given, 
but there are no dosage forms for children. Earlier in the 
review article we proved the relevance and appropriate-
ness of introduction of a dosage form with L-carnitine 
for children into medical practice [3, 6]. 
According to the guidelines of the European Medi- 
cines Agency EMEA “Formulations of choice for the pe- 
diatric population (EMEA/CHMP/PEG/196810/2005)” 
and ICH E11 “Clinical Investigation of medicinal pro- 
ducts in the pediatric population” these patients are usu-
ally in a high-risk group:
• premature infants (aged less than 37 weeks);
• newborns (aged 0–28 days);
• younger children (aged from 1 month to 2 years);
• children of the preschool age (aged from 2 to 5 years).
For these patients mainly drugs that are adminis-
tered orally (syrups, solutions, drops, suspensions) are 
used with the concentration of the active ingredient, 
convenient dosing in proportion to the body weight of 
the child. It is undesirable to use certain preservatives 
(benzyl alcohol, salts of benzoic acid, lactic acid, etc.), 
sweeteners (aspartame, xylene, etc.), some flavouring 
and colouring agents. After the analysis of the current 
scientific data the composition of the dosage form for 
children in the form of the syrup based on L-carnitine 
has been selected. 
The syrup of L-carnitine, 10%, belongs to drugs of 
the metabolic action with the anabolic effect. It shows 
neuro-, hepato-and cardio protective effects, improves 
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transmission of nerve impulses in synapses and axons 
by increasing neurotransmitters and the lipid metabolism, 
stimulates the cellular immunity, reduces the symptoms 
of physical and mental fatigue. It is indicated for use 
primarily in infants and children up to 2-5 years old with 
the primary and secondary carnitine-deficiency condi-
tions and it is possible to use in older children. 
Taking into account the abovementioned we set a 
goal to develop the technology of a dosage form for 
children that contains L-carnitine for further introduc-
tion into the pharmaceutical production.
Experimental Part
When developing pediatric drugs the following as-
pects be must taken into account: the age category of 
patients treated by the given drug, interaction of the ac-
tive ingredient with excipients, possible side effects of 
preservatives, sweeteners, colouring agents and other 
excipients used in creation of a dosage form for chil-
dren. The most common dosage forms for children are 
syrups. They are thick, clear liquids containing one or 
more active substances dissolved in concentrated aqueous 
solutions of sucrose or other sugars, and they have a typi-
cal taste and odour depending on the composition [2]. 
To achieve this goal we set the following tasks:
• to determine the qualitative composition of the drug 
base according to the literary analysis of the existing 
similar drugs with L-carnitine;
• to select the quantitative content of the drug base;
• to develop the manufacturing technology for the drug;
• to study the pharmacotechnological indicators of the 
dosage form developed.
L-carnitine is very soluble in water and very hygro-
scopic. Solubility in water is 2500 mg/ml. Considering 
the high hygroscopicity the crystalline L-carnitine is 
used mainly in liquid dosage forms and beverages and 
practically is not used in solid dosage forms (without 
coating), BAA (SHP) and dry food products. In neutral 
and weakly acidic aqueous solutions L-carnitine is sta-
ble, but in long storage in the alkaline or oxidized me-
dium it gradually decomposes especially at high tem-
peratures (above 90°C).
L-carnitine is thermostable (at 60°C and 90°C) in a 
dry state and in solutions.
Excipients containing in the syrup of levocarnitine, 
10%, used in its development are described in the Euro-
pean Pharmacopoeia and included in “The list of names 
of excipients containing in the composition of drugs” 
approved by the Ministry of Public Health of Ukraine 
from 19.06.2007, No.339 [4].
The syrup of levocarnitine, 10%, contains excipi-
ents having the following functions: preservatives, pH 
modifiers, sweeteners and flavouring agents (flavours 
of taste and odour) (Table 1). 
Development of the drug – the syrup of levocarni-
tine, 10%, was conducted using the substance of levocar-
nitine by NANJING PHARMACEUTICAL FACTORY 
company from China according to the following stages:
• the study of the compositions of the existing analo- 
gues of the drug and physicochemical and techno- 
logical properties of the drug components;
• the experimental testing of the composition of com- 
ponents and its correction for providing the necessary 
technological and organoleptic properties.
Several pharmaceutical formulations of excipients 
in different proportions were composed on the basis of 
analysis of the component composition of the drugs-ana- 
logues described in literature, the results of determina-
tion of physicochemical and technological properties of 
the substance, scientific data about the pharmacological 
activity of L-carnitine.
The concentration of the active ingredient (10%) 
was selected on the basis of the available pharmaco-
logical data taking into account the ease of dosing for 
groups of children of diferent age.
Special requirements to drugs for children require 
minimizing the possible negative effects on the child’s 
Table 1
Functional purpose of components [5]
The name  
of excipients
Functions  
in a dosage form
The influence on technological parameters and characteristics  




Introduceed into the composition of a drug as a sweetener and preservative. 
The coefficient of sweetness in relation to sucrose is about 0.6; thus, for obtaining 
a sweet taste the use of rather high concentrations of sorbitol (15-20% or 
higher) is required. It has a marked osmotic effect, reduces the activity of 
water in solutions, and due to it the environment that is unfavourable for 
microbial growth creates. The concentration of sorbitol being more than 
30-35% is sufficient to obtain stable solutions, the concentration of sorbitol 






Introduced into the formulation as a modifier of acidity and preservative. 
Introduction of citric acid shifts pH to the acidic medium, and it increases the 
resistance of the active substance to oxidation, improves taste characteristics, 
and provides additional preservative effect due to the influence of micro-
organisms on the citric acid cycle. It inhibits malate dehydrogenase, isocitra te 
dehydrogenase, succinate dehydrogenase and other enzymes of bacteria
Food flavouring 
(lemon, orange, mint)
Flavour Introduced into the drug for odour correction 
Purified water Solvent Creates the required concentration of the active ingredient and excipients
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organism together with preservation of high organo-
leptic properties. It is known that such preservatives as 
benzoic acid and its salts increase the risk of hepatitis 
B in infants, benzyl alcohol is toxic and causes allergic 
reactions in infants and children under 3 years, the con-
centration of ethanol in the drug for children under 3 
years should not exceed 0.5%. The choice of a sweeten-
er is limited by a possible negative effect due to aspar-
tame, some sugars, etc., or unsatisfactory organoleptic 
and technological properties (glyciram thaumatin, etc.).
Organoleptic properties were evaluated by selecting 
the concentration of the main taste in relation to taste of 
the solution taken from a standard with a bitter-astrin-
gent taste (Table 2).
Substances, which structure is the closest to the struc-
ture of natural substances, have qualitative organoleptic 
and technological properties, therefore, sorbitol in com-
bination with citric acid, sorbic acid, some sweeteners 
approved for use in drugs for newborns (sucralose, neo- 
hesperydyn, etc.) and flavourings with the odour of mint, 
lemon and orange approved for use in food products 
and drugs have been offered as the substances provi- 
ding organoleptic and preservative properties.
The concentration of sorbitol of 45% was selected 
on the basis of available data on the preservative effect 
of sorbitol at different concentrations taking into account 
the maximum recommended daily dose of sorbitol.
The concentration of flavours was chosen experimen-
tally. The content of a flavouring (mint, lemon, orange) 
in the dosage form is given in Table 3.
Thus, the optimal amount of a flavouring in the do- 
sage form is 0.03%.
Results and Discussion
On the basis of the data concerning the pharmaco-
logical activity of levocarnitine the concentration of the 
active substance has been chosen, and experimentally the 
concentration of excipients in the dosage form of levo-
carnitine syrup, 10%, for children has been determined.
Based on the results obtained the composition of 
the drug has been suggested; it is given in Table 4.
The manufacturing technology of the drug developed 
(Figure) is acceptable for the enterprises, which produce 
liquid dosage forms and can be introduced into pharma-
ceutical manufacture with the purpose of expanding the 
nomenclature of domestic products.
In the process of our experiment the control of the 
samples quality was conducted by the pharmacotechno- 
Table 2
The preservative action and organoleptic properties of sorbitol in different concentrations
Concentration 10.0% 20.0% 30.0% 45.0%
Preservative action * * ** ***
Taste + + ++ +++
Note. Preservative action: * – weak effect; ** – Moderate effect; *** – Pronounced effect. Sweet Taste: + – Unexpressed; ++ – Weakly 
expressed; +++ – Expressed
Table 3
The content of a flavoring in the dosage form
Concentration 0.02% 0.03% 0.05% 0.075% 0.10%
Odour + ++ ++ +++ ++++
Note: + – Weakly expressed; ++ – Distinct, pleasant; +++ – Strongly expressed; ++++ – Strongly expressed (unpleasant)
Table 4
The composition of the medicinal form  
of levocarnitine syrup, 10%, for children




Flavouring (mint, lemon, and 
orange) 0.037
Purified water less than 100.000 ml
Table 5
Pharmacotechnological indicators of quality of levocarnitine syrup, 10%
The name of the 
component The requirements of the SPhU Actual results
Description
(visually)
A transparent colourless liquid with a sour-
sweet taste and with odour that is typical of the 
respective flavour (lemon, mint, orange)
A transparent colourless liquid with a sour-
sweet taste and with odour that is typical of the 
respective flavour (lemon, mint, orange)
рН From 4.5 to 5.2 (SPhU 2.2.3.) 4.81
Relative density From 1.14 to 1.22 (SPhU 2.2.5. method 1) 1.19
Transparency of the 
solution
The solution should be transparent  
(SPhU 2.2.1.) transparent
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logical indicators of the drug developed. They are shown 
in Table 5.
CONCLUSIONS
1. The literary analysis conducted has proven the expe-
dience of using drugs containing L-carnitine for the treat-
ment of disorders of the energy metabolism in children.
2. The qualitative and quantitative analysis of exci- 
pients in the compositions of the available drugs with 
L-carnitine has been performed. The results of this work 
have been included in the pharmaceutical development 
of the drug.
3. In the research technological laboratory at the 
National University of Pharmacy the technology of a 
liquid dosage form for children in the form of a syrup 
has been developed.
4. The pharmacotechnological characteristics of the 
product developed have been studied. The composition of 
the drug corresponds to the requirements of the SPhU.
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РОЗРОБКА ДИТЯЧОЇ ЛІКАРСЬКОЇ ФОРМИ З L-КАРНІТИНОМ
О.М.Безчаснюк, Т.В.Зборовська, С.М.Коваленко
Ключові слова: виробництво дитячих лікарських форм; L-карнітин; сироп
Лікування метаболічних розладів у дітей різного віку та дорослих є сучасною і складною про-
блемою сьогодення. Велика увага на сьогодні приділяється лікуванню препаратом на основі 
L-карнітину. Проведені наукові дослідження з розробки лікарського препарату для дітей у формі 
сиропу, що містить L-карнітин. На сучасному фармацевтичному ринку України відсутні пре-
парати з дитячими дозуваннями L-карнітину. Прийнятними лікарськими формами для дітей 
різного віку є рідкі форми, в тому числі сиропи. Нами було розроблено та апробовано в на-
вчально-науковій технологічній лабораторії лікарських форм Національного фармацевтичного 
університету технологію виробництва препарату для впровадження в фармацевтичну про-
мисловість країни. Для розробки технології були проаналізовані літературні джерела та ви-
значено ряд аналогічних препаратів, досліджено їх якісний склад. Експериментальним шляхом 
встановлено кількісний склад препарату, що розробляється. На підставі даних про фарма-
кологічну активність L-карнітину підібрана концентрація діючої субстанції. Проведено підбір 
консервантів, модифікаторів кислотно-лужних властивостей, коригентів запаху та смаку. 
Також нами було встановлено послідовність технологічних операцій, які дозволяють створи-
ти якісний препарат. Постадійне виробництво препарату викладено в блок-схемі технологіч-
ного процесу. Вивчені фармакотехнологічні показники якості запропонованої лікарської форми, 
а саме зовнішній вигляд препарату, рН, відносна щільність та прозорість отриманого роз-
чину. Результати проведеної роботи будо внесено до фармацевтичної розробки препарату.
РАЗРАБОТКА ДЕТСКОЙ ЛЕКАРСТВЕННОЙ ФОРМЫ С L-КАРНИТИНОМ
Е.М.Безчаснюк, Т.В.Зборовская, С.Н.Коваленко
Ключевые слова: производство детских лекарственных форм; L-карнитин; сироп
Лечение метаболических расстройств у детей разного возраста и у взрослых является тя-
желой проблемой современности. Большое внимание сегодня уделяется лечению препарата-
ми на основе L-карнитина. Проведены научные исследования по разработке лекарственного 
препарата для детей в форме сиропа, содержащего L-карнитин. На современном фармацев-
тическом рынке Украины отсутствуют препараты с дозировками для детей с L-карнитином. 
Приемлемыми лекарственными формами для детей разного возраста являются жидкие фор-
мы, в том числе сиропы. Нами была разработана и апробирована в учебно-научной технологи-
ческой лаборатории лекарственных форм Национального фармацевтического университета 
технология производства препарата для внедрения в фармацевтическую промышленность 
страны. Для разработки технологии были проанализированы литературные источники и опре-
делен ряд аналогичных препаратов, исследован их качественный состав. Экспериментальным 
путем установлен количественный состав разрабатываемого препарата. На основании дан-
ных о фармакологической активности L-карнитина подобрана концентрация действующей 
субстанции. Проведен подбор консервантов, модификаторов кислотно-щелочных свойств, ко-
ригент запаха и вкуса. Также нами была установлена последовательность технологических 
операций, которые позволяют создать качественный препарат. Постадийное производство 
препарата изложено в блок-схеме технологического процесса. Изучены фармакотехнологиче-
ские показатели качества предложенной лекарственной формы, а именно внешний вид пре-
парата, рН, относительная плотность и прозрачность полученного раствора. Результаты 
проведенной работы были внесены в фармацевтическую разработку препарата.
